Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Multiple nucleic acid amplification tests (NATs) are available for the detection of SARS-CoV-2 in clinical specimens, including Laboratory Developed Tests (LDT), commercial high-throughput assays and point-of-care tests. Some assays were just recently released and there is limited data on their clinical performance. We compared the Xpert® Xpress SARS-CoV-2 (Cepheid) and Vivalytic VRI Panel (Schnelltest COVID-19) (Bosch) point-of-care tests with four high-throughput assays and one LDT, the cobas® SARS-CoV-2 test (Roche), the Allplex™ 2019-nCoV Assay (Seegene), the SARS-CoV-2 AMP (Abbott) Kit, the RealStar® SARS-CoV-2 RT-PCR Kit 1.0 (altona) as well as an assay using a SARS-CoV-2 RdRP gene specific primer and probe set. Samples from patients with confirmed SARS-CoV-2 infection, samples from the first and second SARS-CoV-2-PCR External Quality Assessment (EQA) (INSTAND e.V.) and a 10-fold serial dilution of a SARS-CoV-2 cell culture (SARS-CoV-2 Frankfurt 1) supernatant were examined. We determined that the NAT assays examined had a high specificity. Assays using the N gene as target demonstrated the highest sensitivity in the serial dilution panel, while all examined NAT assays showed a comparable sensitivity when testing clinical and EQA samples.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7885623PMC
http://dx.doi.org/10.1016/j.jviromet.2021.114102DOI Listing

Publication Analysis

Top Keywords

sars-cov-2
10
nucleic acid
8
acid amplification
8
amplification tests
8
tests nats
8
high-throughput assays
8
point-of-care tests
8
serial dilution
8
nat assays
8
assays
6

Similar Publications

Background: Following SARS-CoV-2 infection, ~10-35% of COVID-19 patients experience long COVID (LC), in which debilitating symptoms persist for at least three months. Elucidating biologic underpinnings of LC could identify therapeutic opportunities.

Methods: We utilized machine learning methods on biologic analytes provided over 12-months after hospital discharge from >500 COVID-19 patients in the IMPACC cohort to identify a multi-omics "recovery factor", trained on patient-reported physical function survey scores.

View Article and Find Full Text PDF

Introduction: Severe viral infections are common in patients requiring admission to intensive care units (ICU). Furthermore, these patients often have additional secondary or co-infections. Despite their prevalence, it remains uncertain to what extent those additional infections contribute to worse outcomes for patients with severe viral infections requiring ICU admission.

View Article and Find Full Text PDF

Diagnostic approach for post-COVID-19 mucormycosis.

Minerva Dent Oral Sci

September 2025

Department of Dental Research Cell, Dr. D.Y. Patil Dental College and Hospital, Dr. D.Y. Patil Vidyapeeth, Pune, India.

The COVID-19 pandemic, particularly in India, continues to pose a major threat to public health owing to the large number of patients that remain affected. The second wave of COVID-19 has brought with it several opportunistic diseases caused by bacteria and fungi, including mucormycosis, which is a well-known fungal infection primarily encountered in immunocompromised individuals through inhalation. In recent times, mucormycosis has become increasingly common in COVID-19 patients, particularly those with comorbidities such as diabetes, and has been observed to induce secondary infections as it spreads with COVID-19 treatment.

View Article and Find Full Text PDF

This study examined sociodemographic and health-related determinants of self-reported unmet health service needs to better understand the factors contributing to inequities among adults aged 50 and older during the COVID-19 pandemic in Latvia. Data from the longitudinal SHARE study-Corona Surveys 1 and 2, and Wave 8-were analysed using logistic regression. A total of 647 cases from Latvia (62.

View Article and Find Full Text PDF